A live webcast will be available on the Investors section under Event & Webcasts of the Company's website: http://hansamedical.com/en/investors-media/events/. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

About Hansa Medical
Hansa Medical (NASDAQ Stockholm:HMED) is a biopharmaceutical company developing novel immunomodulatory enzymes for organ transplantation and acute autoimmune diseases. The Company’s lead product, imlifidase, is a proprietary antibody-degrading enzyme in late-stage clinical development for kidney transplant patients and has significant potential for further development in other solid organ transplantation and in acute autoimmune indications. Hansa also has a strong pipeline of preclinical projects that may provide a second wave of potential drugs. Under the project name NiceR, the Company is developing novel immunoglobulin-cleaving enzymes for repeat dosing in relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden.

For further information, please contact:

Company:
Emanuel Björne, Vice President Business Development and Investor Relations
Hansa Medical AB (Publ)
Mobile: +46 70 717 5477
E-mail: emanuel.bjorne@hansamedical.com


http://hansamedical.com

Swedish Investor and Media Relations:
Cord Communications
Mikael Widell
+46 70-311 99 60

U.K. Investor and Media Relations:
FTI Consulting
Simon Conway/ Stephanie Cuthbert
+44 (0)20 3727 1000

U.S. Investor and Media Relations:
Argot Partners
Stephanie Marks / David Rosen (media)
+1 212 600 1902